1 Oct 2026, 09:30
Presentations—
NUZNEURIZON THERAPEUTICS LIMITED
Announcement history available from 1 August 2025
Fromto
17 Sept 2026, 13:59
Director Interests—
15 Sept 2026, 18:17
Securities Administration—
10 Sept 2026, 09:53
Securities AdministrationMS
10 Sept 2026, 09:18
Securities Administration—
9 Sept 2026, 09:55
Company UpdateMS
7 Sept 2026, 09:02
Company AdministrationMS
26 Aug 2026, 11:49
Securities Administration—
25 Aug 2026, 15:03
Company Administration—
25 Aug 2026, 14:58
Financial ResultsMS
24 Aug 2026, 17:06
Securities Administration—
13 Aug 2026, 09:46
Company Administration—
11 Aug 2026, 09:47
Capital Raising—
31 July 2026, 15:32
Quarterly ReportsMS
31 July 2026, 15:21
Capital RaisingMS
29 July 2026, 13:56
Presentations—
17 July 2026, 09:25
Company UpdateMS
16 July 2026, 11:39
Securities Administration—
14 July 2026, 16:36
Securities Administration—
2 July 2026, 09:20
Company Administration—
1 July 2026, 09:48
Director Interests—
30 June 2026, 09:13
Securities Administration—
29 June 2026, 16:31
Securities Administration—
23 June 2026, 11:25
Company Update—
19 June 2026, 11:15
Securities Administration—
17 June 2026, 09:07
Company UpdateMS
12 June 2026, 09:07
Company UpdateMS
2 June 2026, 17:32
Securities Administration—
28 May 2026, 15:24
Presentations—
27 May 2026, 09:20
Company UpdateMS
13 May 2026, 09:19
Company UpdateMS
12 May 2026, 16:27
Director Interests—
12 May 2026, 16:22
Director Interests—
11 May 2026, 13:20
Presentations—
8 May 2026, 09:06
Company Administration—
4 May 2026, 12:15
Director Interests—
30 Apr 2026, 16:17
Presentations—
30 Apr 2026, 16:09
Securities Administration—
30 Apr 2026, 09:38
Quarterly ReportsMS
21 Apr 2026, 09:40
Securities Administration—
21 Apr 2026, 09:33
Securities Administration—
16 Apr 2026, 14:30
Company Administration—
16 Apr 2026, 09:28
Capital RaisingMS
10 Apr 2026, 09:58
Presentations—
1 Apr 2026, 16:39
Securities Administration—
1 Apr 2026, 16:25
Securities Administration—
1 Apr 2026, 09:46
Company UpdateMS
26 Mar 2026, 08:18
Director Interests—
20 Mar 2026, 09:48
Letters & Addresses—
20 Mar 2026, 08:40
Presentations—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 1 Oct 2026, 09:30 | Dr Chris Bremer commences as Neurizon CEO | Presentations | — | 14014 | |
| 17 Sept 2026, 13:59 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 15 Sept 2026, 18:17 | Notification of cessation of securities - NUZ | Securities Administration | — | 06027 | |
| 10 Sept 2026, 09:53 | Neurizon Announces Partial Redemption of Convertible Notes | Securities Administration | MS | 06009 | |
| 10 Sept 2026, 09:18 | Application for quotation of securities - NUZ | Securities Administration | — | 06020 | |
| 9 Sept 2026, 09:55 | NIH funds Expanded Access Program for NUZ-001 in ALS | Company Update | MS | 11001 | |
| 7 Sept 2026, 09:02 | Neurizon Appoints Chief Executive Officer | Company Administration | MS | 12019 | |
| 26 Aug 2026, 11:49 | Application for quotation of securities - NUZ | Securities Administration | — | 06020 | |
| 25 Aug 2026, 15:03 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 25 Aug 2026, 14:58 | Appendix 4E and 2026 Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 24 Aug 2026, 17:06 | Notification regarding unquoted securities - NUZ | Securities Administration | — | 06021 | |
| 13 Aug 2026, 09:46 | Elanco representative appointed as Neurizon Board Observer | Company Administration | — | 12008 | |
| 11 Aug 2026, 09:47 | Neurizon Completes Initial Drawdown under R&D Facility | Capital Raising | — | 03022 | |
| 31 July 2026, 15:32 | Appendix 4C & Quarterly Update | Quarterly Reports | MS | 19004, 19009 | |
| 31 July 2026, 15:21 | Neurizon Enters Strategic R&D Financing Facility | Capital Raising | MS | 03022 | |
| 29 July 2026, 13:56 | Melbourne investor briefing presentation | Presentations | — | 03026 | |
| 17 July 2026, 09:25 | HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27 | Company Update | MS | 11001 | |
| 16 July 2026, 11:39 | Application for quotation of securities - NUZ | Securities Administration | — | 06020 | |
| 14 July 2026, 16:36 | Notification of cessation of securities - NUZ | Securities Administration | — | 06027 | |
| 2 July 2026, 09:20 | Neurizon Invites Investors to Melbourne Briefing | Company Administration | — | 12008 | |
| 1 July 2026, 09:48 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 30 June 2026, 09:13 | Proposed issue of securities - NUZ | Securities Administration | — | 06013 | |
| 29 June 2026, 16:31 | Notification of cessation of securities - NUZ | Securities Administration | — | 06027 | |
| 23 June 2026, 11:25 | New NUZ-001 Mechanistic Data Presented at BIO 2026 | Company Update | — | 03026, 11001 | |
| 19 June 2026, 11:15 | Application for quotation of securities - NUZ | Securities Administration | — | 06020 | |
| 17 June 2026, 09:07 | Neurizon executes long-term supply agreement with Elanco | Company Update | MS | 11001 | |
| 12 June 2026, 09:07 | HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule | Company Update | MS | 11001 | |
| 2 June 2026, 17:32 | Application for quotation of securities - NUZ | Securities Administration | — | 06020 | |
| 28 May 2026, 15:24 | Webinar presentation - Regimen I expands to 240 participants | Presentations | — | 03026, 14014 | |
| 27 May 2026, 09:20 | HEALEY ALS Trial Regimen I Expands to 240 Participants | Company Update | MS | 11001 | |
| 13 May 2026, 09:19 | Ethics Approval Received for NUZ-001 Oral Liquid P1 Study | Company Update | MS | 11001 | |
| 12 May 2026, 16:27 | Final Director's Interest Notice | Director Interests | — | 02010 | |
| 12 May 2026, 16:22 | Initial Director's Interest Notice | Director Interests | — | 02008 | |
| 11 May 2026, 13:20 | Australian Microcap Investment Conference Presentation | Presentations | — | 03026 | |
| 8 May 2026, 09:06 | Neurizon Strengthens Board for the Next Growth Phase | Company Administration | — | 12001, 12008 | |
| 4 May 2026, 12:15 | Change of Director's Interest Notices | Director Interests | — | 02009 | |
| 30 Apr 2026, 16:17 | Neurizon investor briefing presentation | Presentations | — | 03026 | |
| 30 Apr 2026, 16:09 | Application for quotation of securities - NUZ | Securities Administration | — | 06020 | |
| 30 Apr 2026, 09:38 | Appendix 4C & Quarterly Update | Quarterly Reports | MS | 19003, 19008 | |
| 21 Apr 2026, 09:40 | Section 708A Cleansing Statement | Securities Administration | — | 06018 | |
| 21 Apr 2026, 09:33 | Application for quotation of securities - NUZ | Securities Administration | — | 06020 | |
| 16 Apr 2026, 14:30 | Neurizon Investor Briefings Invitation | Company Administration | — | 12008 | |
| 16 Apr 2026, 09:28 | Placement of Entitlement Offer Shortfall | Capital Raising | MS | 06008 | |
| 10 Apr 2026, 09:58 | Investor Presentation - April 2026 | Presentations | — | 03026 | |
| 1 Apr 2026, 16:39 | Section 708A Cleansing Statement | Securities Administration | — | 06018 | |
| 1 Apr 2026, 16:25 | Application for quotation of securities - NUZ | Securities Administration | — | 06020 | |
| 1 Apr 2026, 09:46 | NUZ-001 Data Shows Multi-Pathway Protein Clearance | Company Update | MS | 11001 | |
| 26 Mar 2026, 08:18 | Change of Director's Interest Notices x4 | Director Interests | — | 02009 | |
| 20 Mar 2026, 09:48 | Notification of Expiry of NUZOA Listed Options | Letters & Addresses | — | 06009, 16001 | |
| 20 Mar 2026, 08:40 | Neurizon presents at HEALEY ALS Platform Trial Webinar | Presentations | — | 03026 |
1–50 of 124
1 / 3